Calu-6 Transfection Kit (Lung Carcinoma, HTB-56)

Description

Purchase Orders: Click “Add to Cart” button to order, then email PO to orders@altogen.com.

Product Availability: In Stock.

Transfection Reagent for Calu-6 Cells (Lung Carcinoma Cell, HTB-56)

• Liposome formulation enhances lipid mediated transfection efficiency
• Optimized easy-to-use transfection protocol provided for transfection of siRNA, DNA, mRNA, and microRNA
• Kit includes Transfection Enhancer reagent and recommended transfection protocol
• Download in vitro Calu-6 transfection protocol: [PDF]
• Download Calu-6 CRISPR/Cas9 transfection protocol: [PDF]
• Download PowerPoint presentation for Calu-6 cells transfection kit: [PPT]
• UPC/GTIN/EAN: 860002089749
• Brand: ALTOGEN®, developed and manufactured by Altogen Biosystems

Transfection Efficiency:

Reagent exhibits at least 90% transfection efficiency of siRNA delivery. Transfection efficiency was determined by qRT-PCR.

Product Description:

This transfection kit is specially designed for the Calu-6 cells, a human lung adenocarcinoma cell line. Transfection reagent supplemented by complex condenser and transfection enhancer ensures high efficiency in delivering cargo biomolecules into these cells.

Transfection Protocol and SDS:

Download Altogen Biosystems Calu-6 Transfection Protocol: [PDF]

Download SDS: [PDF]

Calu-6 Cell Line:

Calu6 is a human non-small cell lung cancer cell line that was derived from a lung adenocarcinoma. It is commonly used as a model system for studying lung cancer biology and for investigating the efficacy of various drugs and therapies for the treatment of this deadly disease. Calu6 cells grow in vitro as adherent monolayers and have a morphology that is characteristic of lung cancer cells. Lung cancer is considered the leading cause of cancer death worldwide among both women and men, mainly occurring in older people, with an average patient age of 70 years and less than 2% of all diagnosed patients being younger than 45, per the American Cancer Society (ACS). Moreover, it is considered the most preventable cancer, affecting smokers 15 to 30 times more often than people who do not smoke. The Calu-6 epithelial cell line was derived from tissue of a 61-year-old Caucasian female patient with anaplastic carcinoma (lung cancer). Anaplastic carcinoma is a condition in which cells rapidly proliferate, but lose their original differentiation, leading to high malignancy. The modal chromosome number in the Calu-6 cell line is 59, and these cells are highly utilized in investigative research. Calu-6 cells have been used to better understand the relationship between antimycin A (AMA) and lung cancer cells. It has been suggested in studies that changes of reactive oxygen species (ROS) and glutathione (GSH) affect apoptosis in AMA-treated Calu-6 cells. Also, using AMA as a mitochondrial electron transport inhibitor decreased the growth of Calu-6 cells by inducing a G1 arrest of the cell cycle and apoptosis. Tiron, a ROS scavenger, protects human lung cancer Calu-6 cells against antimycin A-induced cell death. The Calu-6 cell line has also been employed in research of the mechanism underlying pressure transduction of the renin-angiotensin system. Altogen Biosystems provides pre-optimized transfection reagent kits for the Calu-6 anaplastic lung cancer cell line that yield around 90% transfection efficiency, as per qRT-PCR.

Mutations:

Data:

Figure 1. GAPD mRNA levels were quantified using real-time RT-PCR in the Calu-6 cells transfected with siRNAs targeting GAPD or non-silencing siRNA. Forty-eight hours post-transfection, the cells were harvested and analyzed by real-time RT-PCR for GAPDH mRNA expression levels. Data were normalized against the 18S rRNA signal. Control samples were either mock-transfected or untreated. Values are normalized to untreated sample. Data are means ± SD (n=3).

Figure 2. Protein expression of GAPDH in Calu-6 cells. DNA plasmid expressing GAPDH or siRNA targeting GAPDH were transfected into Calu-6 cells following Altogen Biosystems transfection protocol. At 72 hours post-transfection the cells were analyzed by Western Blot for protein expression levels (normalized by total protein, 10 µg of total protein loaded per each well). Untreated cells used as a negative control.

Selected Calu6 transfection reagent citation references:

• Clin Lung Cancer. 2015 Nov;16(6):e121-9. miR Profiling Identifies Cyclin-Dependent Kinase 6 Downregulation as a Potential Mechanism of Acquired Cisplatin Resistance in Non-Small-Cell Lung Carcinoma. Bar et al [PDF]
• Cancer Research. 2011 71(15):5144-53. Inhibition of miR-193a expression by… Iliopoulos et al [PDF]

Altogen Biosystems manufacturers preoptimized transfection kits for cancer research. Reagents and transfection protocols are optimized for individual cancer cell lines. Altogen Biosystems developed two types of in vivo delivery kits for animal research: Tissue-targeted reagents (delivery into liver, pancreas, and kidney tissues), and in vivo biodistribution reagents (PEG-Liposome, Nanoparticle, Lipid, and Polymer-based kits). Optimized transfection protocols provide efficient intracellular delivery of proteins, DNA, and RNA molecules in vitro and in vivo. Read more about transfection technology at Altogen’s Transfection Resource. Altogen Labs provides GLP compliant contract research studies for preclinical research, IND applications, and drug development. Our biology CRO services include: efficacy xenograft studies, development of stable cell lines, cell-based and tissue targeted RNAi studies, safety pharm/tox assays, and other studies (for more details please visit AltogenLabs.com).

Volume Options:

• 0.5 ml (Catalog #1727)
• 1.5 ml (Catalog #1728)
• 1.5 ml CRISPR (Catalog #2125)
• 8.0 ml (Catalog #7027)

Purchase Orders: Click “Add to Cart” button to order, then email PO to orders@altogen.com.

Product Availability: In Stock.